I-Corps: Establishing an innovation ecosystem for technology transition of MEMS-based drug infusion pumps

I-Corps公司提出的泵通过提供小型化的鼠标兼容外形、无线电源和远程控制功能，以及完全可定制的慢性药物给药能力，解决了关键的未满足需求。该团队解决了学术界和工业界在科学发现和临床前药物研究的实验动物研究中对泵的迫切需求。在临床前验证的早期阶段应用泵技术可以促进新药的开发，并实现新的治疗模式。该技术的可扩展性也有可能将目标市场从实验室动物研究扩展到人类患者护理。长期目标是利用该技术与其他方法无法提供的新疗法相结合，以最大限度地提高治疗效益，同时最大限度地减少副作用，为人类提供患者特定的剂量配置。I-Corps的努力将产生一项计划，将提议的创新转化为市场、原型制造和技术演示。该项目旨在将一种用于药物开发和治疗的微型植入式输液泵的创新技术转化为药物。该泵专门解决了当前技术的局限性，并以紧凑的外形提供准确和可定制的剂量。该技术通过无线通信和信息技术的集成集成了下一代能力。这些先进的输送系统和新疗法不仅为推进研究，而且为技术商业化和卫生保健成果提供了丰富的机会。

The pump proposed in this I-Corps effort addresses critical unmet needs by providing a miniaturized mouse-compatible form factor, wireless power and remote control features, and fully-customizable dosing capability for chronic drug administration studies. The team addresses the immediate need from academia and industry for pumps in both laboratory animal research for scientific discovery and preclinical drug studies. Applying the pump technology at the earliest stage of preclinical validation may improve the development of new drugs and enable new treatment paradigms. The scalability of the technology also has the potential to extends the addressable market beyond laboratory animal research to human patient care, The long-term goal is to leverage this technology in combination with novel therapeutics that cannot be delivered by other means to provide patient-specific dosing profiles in humans in a manner that maximizes therapeutic benefit while minimizing side effects. This I-Corps effort will result in a plan to transition the proposed innovation to the marketplace, fabrication of prototypes, and technology demonstration.This project seeks to transition innovative technology, a miniature implantable infusion pump, for drug development and treatment. The pump specifically addresses limitations of current technologies and offers accurate and customizable dosing in a compact form factor. The technology incorporates next generation capability through the integration of wireless communication and information technology. These advanced delivery systems and novel therapeutics present a fertile opportunity for advancing not only research but technology commercialization and health care outcomes.